Literature DB >> 26354988

Evaluation of outcome measures for neurogenic claudication: A patient-centered approach.

John D Markman1, Jennifer S Gewandter2, Maria E Frazer2, Christine Pittman2, Xueya Cai2, Kushang V Patel2, Babak S Jahromi2, Robert H Dworkin2, Laurie B Burke2, John T Farrar2.   

Abstract

OBJECTIVES: To determine whether patients with neurogenic claudication associated with lumbar spinal stenosis would prefer a treatment that makes it possible for them to walk farther or walk with less pain; to examine associations between this treatment preference and patient-reported and in-clinic treadmill testing measures of walking ability and walking-associated pain.
METHODS: In this cross-sectional study, 269 patients with neurogenic claudication were asked to report their pain intensity when walking, complete the Swiss Spinal Stenosis Questionnaire, rank their outcome preferences for treatment, and undergo standardized treadmill testing, including measures of final pain rating and time to first pain of moderate intensity (Tfirst). Descriptive statistics were used to characterize patient preferences for treatment outcome. Associations between self-report questionnaires and standardized treadmill testing outcomes were evaluated using Spearman correlations.
RESULTS: Seventy-nine percent of patients expressed a preference for treatment that allowed them to walk with less pain. Preference for reduced pain was associated with higher pain during daily walking, along with a shorter Tfirst and higher final pain severity on treadmill testing. In contrast, patient preference for treatment outcome was not associated with self-reported measures of daily walking capacity or walking distance on the treadmill.
CONCLUSIONS: A majority of patients with neurogenic claudication prioritized walking with reduced pain over walking farther. Reduction in pain while walking may therefore constitute a sufficient patient-focused treatment outcome for the majority of these patients. These results have implications for clinical trial design and assessment of treatment efficacy in neurogenic claudication.
© 2015 American Academy of Neurology.

Entities:  

Mesh:

Year:  2015        PMID: 26354988      PMCID: PMC4607594          DOI: 10.1212/WNL.0000000000002000

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

1.  Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations.

Authors:  Dennis C Turk; Robert H Dworkin; Laurie B Burke; Richard Gershon; Margaret Rothman; Jane Scott; Robert R Allen; Hampton J Atkinson; Julie Chandler; Charles Cleeland; Penny Cowan; Rozalina Dimitrova; Raymond Dionne; John T Farrar; Jennifer A Haythornthwaite; Sharon Hertz; Alejandro R Jadad; Mark P Jensen; David Kellstein; Robert D Kerns; Donald C Manning; Susan Martin; Mitchell B Max; Michael P McDermott; Patrick McGrath; Dwight E Moulin; Turo Nurmikko; Steve Quessy; Srinivasa Raja; Bob A Rappaport; Christine Rauschkolb; James P Robinson; Mike A Royal; Lee Simon; Joseph W Stauffer; Gerold Stucki; Jane Tollett; Thorsten von Stein; Mark S Wallace; Joachim Wernicke; Richard E White; Amanda C Williams; James Witter; Kathleen W Wyrwich
Journal:  Pain       Date:  2006-10-25       Impact factor: 6.961

2.  United States hospital admissions for lumbar spinal stenosis: racial and ethnic differences, 2000 through 2009.

Authors:  Richard L Skolasky; Anica M Maggard; Roland J Thorpe; Stephen T Wegener; Lee H Riley
Journal:  Spine (Phila Pa 1976)       Date:  2013-12-15       Impact factor: 3.468

Review 3.  Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology.

Authors:  Gary M Franklin
Journal:  Neurology       Date:  2014-09-30       Impact factor: 9.910

Review 4.  Opioids for low back pain.

Authors:  Richard A Deyo; Michael Von Korff; David Duhrkoop
Journal:  BMJ       Date:  2015-01-05

Review 5.  Spinal stenosis and neurogenic claudication.

Authors:  R W Porter
Journal:  Spine (Phila Pa 1976)       Date:  1996-09-01       Impact factor: 3.468

6.  Functional mobility performance in an elderly population with lumbar spinal stenosis.

Authors:  M Whitehurst; L E Brown; S G Eidelson; A D'angelo
Journal:  Arch Phys Med Rehabil       Date:  2001-04       Impact factor: 3.966

7.  A Randomized, Double-blind, Placebo-Controlled Crossover Trial of Oxymorphone Hydrochloride and Propoxyphene/Acetaminophen Combination for the Treatment of Neurogenic Claudication Associated With Lumbar Spinal Stenosis.

Authors:  John D Markman; Jennifer S Gewandter; Maria E Frazer; Nicole M Murray; Shirley A Rast; Michael P McDermott; Amit K Chowdhry; Emilie J Tomkinson; Webster H Pilcher; Kevin A Walter; Robert H Dworkin
Journal:  Spine (Phila Pa 1976)       Date:  2015-05-15       Impact factor: 3.468

8.  An assessment of surgery for spinal stenosis: time trends, geographic variations, complications, and reoperations.

Authors:  M A Ciol; R A Deyo; E Howell; S Kreif
Journal:  J Am Geriatr Soc       Date:  1996-03       Impact factor: 5.562

9.  The state of US health, 1990-2010: burden of diseases, injuries, and risk factors.

Authors:  Christopher J L Murray; Charles Atkinson; Kavi Bhalla; Gretchen Birbeck; Roy Burstein; David Chou; Robert Dellavalle; Goodarz Danaei; Majid Ezzati; A Fahimi; D Flaxman; Sherine Gabriel; Emmanuela Gakidou; Nicholas Kassebaum; Shahab Khatibzadeh; Stephen Lim; Steven E Lipshultz; Stephanie London; Michael F MacIntyre; A H Mokdad; A Moran; Andrew E Moran; Dariush Mozaffarian; Tasha Murphy; Moshen Naghavi; C Pope; Thomas Roberts; Joshua Salomon; David C Schwebel; Saeid Shahraz; David A Sleet; Jerry Abraham; Mohammed K Ali; Charles Atkinson; David H Bartels; Kavi Bhalla; Gretchen Birbeck; Roy Burstein; Honglei Chen; Michael H Criqui; Eric L Ding; E Ray Dorsey; Beth E Ebel; Majid Ezzati; S Flaxman; A D Flaxman; Diego Gonzalez-Medina; Bridget Grant; Holly Hagan; Howard Hoffman; Nicholas Kassebaum; Shahab Khatibzadeh; Janet L Leasher; John Lin; Steven E Lipshultz; Rafael Lozano; Yuan Lu; Leslie Mallinger; Mary M McDermott; Renata Micha; Ted R Miller; A A Mokdad; A H Mokdad; Dariush Mozaffarian; Mohsen Naghavi; K M Venkat Narayan; Saad B Omer; Pamela M Pelizzari; David Phillips; Dharani Ranganathan; Frederick P Rivara; Thomas Roberts; Uchechukwu Sampson; Ella Sanman; Amir Sapkota; David C Schwebel; Saeid Sharaz; Rupak Shivakoti; Gitanjali M Singh; David Singh; Mohammad Tavakkoli; Jeffrey A Towbin; James D Wilkinson; Azadeh Zabetian; Jerry Abraham; Mohammad K Ali; Miriam Alvardo; Charles Atkinson; Larry M Baddour; Emelia J Benjamin; Kavi Bhalla; Gretchen Birbeck; Ian Bolliger; Roy Burstein; Emily Carnahan; David Chou; Sumeet S Chugh; Aaron Cohen; K Ellicott Colson; Leslie T Cooper; William Couser; Michael H Criqui; Kaustubh C Dabhadkar; Robert P Dellavalle; Daniel Dicker; E Ray Dorsey; Herbert Duber; Beth E Ebel; Rebecca E Engell; Majid Ezzati; David T Felson; Mariel M Finucane; Seth Flaxman; A D Flaxman; Thomas Fleming; Mohammad H Forouzanfar; Greg Freedman; Michael K Freeman; Emmanuela Gakidou; Richard F Gillum; Diego Gonzalez-Medina; Richard Gosselin; Hialy R Gutierrez; Holly Hagan; Rasmus Havmoeller; Howard Hoffman; Kathryn H Jacobsen; Spencer L James; Rashmi Jasrasaria; Sudha Jayarman; Nicole Johns; Nicholas Kassebaum; Shahab Khatibzadeh; Qing Lan; Janet L Leasher; Stephen Lim; Steven E Lipshultz; Stephanie London; Rafael Lozano; Yuan Lu; Leslie Mallinger; Michele Meltzer; George A Mensah; Catherine Michaud; Ted R Miller; Charles Mock; Terrie E Moffitt; A A Mokdad; A H Mokdad; A Moran; Mohsen Naghavi; K M Venkat Narayan; Robert G Nelson; Casey Olives; Saad B Omer; Katrina Ortblad; Bart Ostro; Pamela M Pelizzari; David Phillips; Murugesan Raju; Homie Razavi; Beate Ritz; Thomas Roberts; Ralph L Sacco; Joshua Salomon; Uchechukwu Sampson; David C Schwebel; Saeid Shahraz; Kenji Shibuya; Donald Silberberg; Jasvinder A Singh; Kyle Steenland; Jennifer A Taylor; George D Thurston; Monica S Vavilala; Theo Vos; Gregory R Wagner; Martin A Weinstock; Marc G Weisskopf; Sarah Wulf
Journal:  JAMA       Date:  2013-08-14       Impact factor: 56.272

10.  Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication.

Authors:  John D Markman; Maria E Frazer; Shirley A Rast; Michael P McDermott; Jennifer S Gewandter; Amit K Chowdhry; Kate Czerniecka; Webster H Pilcher; Lee S Simon; Robert H Dworkin
Journal:  Neurology       Date:  2014-12-10       Impact factor: 9.910

View more
  3 in total

1.  Only walking matters-assessment following lumbar stenosis decompression.

Authors:  S Budithi; Rohit Dhawan; Andrew Cattell; Birender Balain; David Jaffray
Journal:  Eur Spine J       Date:  2016-11-30       Impact factor: 3.134

2.  SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain.

Authors:  John Markman; Jeffrey Gudin; Richard Rauck; Charles Argoff; Michael Rowbotham; Eva Agaiby; Joseph Gimbel; Nathaniel Katz; Stephen K Doberstein; Mary Tagliaferri; Lin Lu; Suresh Siddhanti; Martin Hale
Journal:  Pain       Date:  2019-06       Impact factor: 7.926

3.  Understanding the mechanisms of a combined physical and psychological intervention for people with neurogenic claudication: protocol for a causal mediation analysis of the BOOST trial.

Authors:  Christine Comer; Hopin Lee; Esther Williamson; Sarah Lamb
Journal:  BMJ Open       Date:  2020-09-02       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.